Key points are not available for this paper at this time.
As SABA overuse is associated with exacerbations and mortality, GINA no longer recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA use from the SABINA programme would indicate a global public health issue.http://bit.ly/33XDrlb
Cabrera et al. (2019) studied this question.